Trials / Recruiting
RecruitingNCT06411821
Ulixertinib in People With Histiocytic Neoplasms
Phase 2 Trial of Ulixertinib for Patients With Histiocytic Neoplasms
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ulixertinib | 300 mg twice daily, for every 28-day cycle. |
Timeline
- Start date
- 2024-05-07
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2024-05-13
- Last updated
- 2025-12-15
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06411821. Inclusion in this directory is not an endorsement.